Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.13
0.252.29%
Last update: Feb 17, 3:04 PM
Comments
Loading...
Entrada Therapeutics Inc Analyst Ratings
TRDANASDAQ
Entrada Therapeutics Analyst Ratings and Price Targets | NASDAQ:TRDA | Benzinga
Entrada Therapeutics Inc has a consensus price target of $23.8 based on the ratings of 5 analysts. The high is $29 issued by Roth MKM on December 5, 2024. The low is $20 issued by Guggenheim on February 11, 2026. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and HC Wainwright & Co. on February 11, 2026, May 20, 2025, and March 31, 2025, respectively. With an average price target of $20 between Guggenheim, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 79.70% upside for Entrada Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
HC Wainwright & Co.
Roth MKM
Oppenheimer
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Entrada Therapeutics
FAQ
What is the target price for Entrada Therapeutics (TRDA) stock?
The latest price target for Entrada Therapeutics (NASDAQ:TRDA) was reported by Guggenheim on February 11, 2026. The analyst firm set a price target for $20.00 expecting TRDA to rise to within 12 months (a possible 79.70% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
The latest analyst rating for Entrada Therapeutics (NASDAQ:TRDA) was provided by Guggenheim, and Entrada Therapeutics initiated their buy rating.
When was the last upgrade for Entrada Therapeutics (TRDA)?
There is no last upgrade for Entrada Therapeutics
When was the last downgrade for Entrada Therapeutics (TRDA)?
There is no last downgrade for Entrada Therapeutics.
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on February 11, 2026 so you should expect the next rating to be made available sometime around February 11, 2027.
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a initiated with a price target of $0.00 to $20.00. The current price Entrada Therapeutics (TRDA) is trading at is $11.13, which is within the analyst’s predicted range.
